Roche Pharmaceuticals’ potential new medication for schizophrenia, bitopertin (RG1678), failed its first two phase III trials. In both trials, adding bitopertin to antipsychotics for 24 weeks failed to improve persistent negative symptoms of schizophrenia as measured by PANSS (Positive and Negative Symptoms Scale) scores when compared to placebo, according to a report released by the company in January.

You can't view details of this content, please login or buy subscription here